Developmental therapeutics
Developmental therapeutics: Invited Discussant 370PD, 371PD and 372PD
Date
09 Sep 2017Session
Developmental therapeuticsPresenters
Stefan SleijferAuthors
S. SleijferAuthor affiliations
- Department Of Medical Oncology And Cancer Genomics Netherlands, Erasmus MC Cancer Institute, 3075 EA - Rotterdam/NL
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3504 - Oncolytic herpesvirus therapy for mesothelioma – a phase I/IIa trial of intrapleural administration of HSV1716 (NCT01721018)
Presenter: Sarah Danson
Session: Developmental therapeutics
Resources:
Abstract
3156 - Early FDG-PET Response Correlates With Dose and Clinical Efficacy in Patients With Microsatellite Stable (MSS) Metastatic CRC (mCRC) Treated With the CEA-CD3 T-cell Bispecific Antibody plus Atezolizumab
Presenter: Federico Sandoval
Session: Developmental therapeutics
Resources:
Abstract
2093 - Dose Escalation/Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activity of BGB-290 in Patients with Advanced Solid Tumors
Presenter: Jason Lickliter
Session: Developmental therapeutics
Resources:
Abstract
1335 - Phase I dose escalation study of M2698, a p70S6K/AKT inhibitor, in patients with advanced cancer
Presenter: A Tsimberidou
Session: Developmental therapeutics
Resources:
Abstract
4813 - A Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in Patients with Advanced Solid Tumors.
Presenter: Drew Rasco
Session: Developmental therapeutics
Resources:
Abstract
2532 - First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.
Presenter: Yasutoshi Kuboki
Session: Developmental therapeutics
Resources:
Abstract
3145 - Phase 1 Study of E7046, a PGE2 Receptor EP-4 Inhibitor That Targets Immunosuppressive Myeloid Cells in the Tumor Microenvironment
Presenter: David Hong
Session: Developmental therapeutics
Resources:
Abstract
3994 - A First in Human Phase 1 Study of KPT-9274, a First in Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or NHL
Presenter: Aung Naing
Session: Developmental therapeutics
Resources:
Abstract
5084 - Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine (gem) in patients (pts) with refractory solid tumors
Presenter: Antoine Italiano
Session: Developmental therapeutics
Resources:
Abstract
1455 - Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: first in human clinical trial
Presenter: Ivan Marquez Rodas
Session: Developmental therapeutics
Resources:
Abstract